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Many of the newer clinical studies proposed for the
management of high-risk prostate cancer include the
use of chemotherapy in addition to androgen depri-
vation. This natural development follows on from
publications endorsing the value of chemotherapy in
metastatic prostate cancer. In 1994, a Canadian group
was the first to show that, by using mitoxantrone com-
bined with steroids, a significant number of patients
could improve their quality of life; and in 2004, the
results from clinical trials of docetaxel were published
showing for the first time that the lives of men af-
fected by hormone-refractory prostate cancer could
be prolonged. One of these published reports came
from a study carried out at the Princess Margaret
Hospital in Toronto, where the original research using
mitoxantrone and steroids had been carried out. The
introduction of docetaxel into prostate cancer treat-
ment is a milestone, and it is natural that this agent
be explored in the adjuvant setting. Given these ad-
vances in care for men with prostate cancer, we are
pleased to enclose with this issue of Current Oncol-
ogy a new patient guide titled Living with Prostate
Cancer. The guide discusses the newer treatment strat-
egies in hormone refractory disease, including the
use of docetaxel.
The World Health Organization continues to re-
port new cases of human infection with avian influ-
enza in the Far East, and although the next influenza
pandemic may not involve the H5N1 strain, a pan-
demic is nonetheless predicted. Various national, re-
gional, and institutional plans have been and continue
to be developed to mitigate the consequences of such
an event. In this issue of the journal, the unique needs
of patients with cancer during a pandemic are
discussed.
The recent increased waiting times for adjuvant
radiation in the province of Ontario led to breast
cancer patients from one Canadian cancer treatment
centre being referred to two centres in the United
States. That situation provided a unique opportu-
nity to compare radiation practices between the two
jurisdictions. Significant and quite substantial varia-
tions in prescribing patterns were seen, likely to im-
pact on patient convenience and resource utilization.
Another article in this issue is concerned with
identifying strategies that might promote a healthy
diet. Despite an extensive search effort, few benefi-
cial dissemination strategies were identified. Much
of the evidence turned out to be descriptive rather
than evaluative, suggesting that controlled studies are
needed to evaluate dissemination strategies and to
compare dissemination and diffusion strategies with
varying messages and varying target audiences.
Finally, a new section, Updates and Develop-
ments in Oncology, which benefits from the editorial
guidance of Richard Ablin, appears in this issue. The
authors of the inaugural review in this series—“Tar-
geting transforming growth factor b to enhance can-
cer immunotherapy”—explain that, to develop
effective cancer therapy modalities, an understand-
ing of the biologic effects that tumour-derived fac-
tors have on immune cells is essential.
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